Historical Valuation
PureTech Health PLC (PRTC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.70. The fair price of PureTech Health PLC (PRTC) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 17.60 USD , PureTech Health PLC is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：17.60
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
PureTech Health PLC (PRTC) has a current Price-to-Book (P/B) ratio of 10.96. Compared to its 3-year average P/B ratio of 5.45 , the current P/B ratio is approximately 101.06% higher. Relative to its 5-year average P/B ratio of 3.99, the current P/B ratio is about 174.65% higher. PureTech Health PLC (PRTC) has a Forward Free Cash Flow (FCF) yield of approximately -24.75%. Compared to its 3-year average FCF yield of -23.23%, the current FCF yield is approximately 6.54% lower. Relative to its 5-year average FCF yield of -20.66% , the current FCF yield is about 19.82% lower.
P/B
Median3y
5.45
Median5y
3.99
FCF Yield
Median3y
-23.23
Median5y
-20.66
Competitors Valuation Multiple
AI Analysis for PRTC
The average P/S ratio for PRTC competitors is 4861.95, providing a benchmark for relative valuation. PureTech Health PLC Corp (PRTC.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PRTC
1Y
3Y
5Y
Market capitalization of PRTC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PRTC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PRTC currently overvalued or undervalued?
PureTech Health PLC (PRTC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.70. The fair price of PureTech Health PLC (PRTC) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 17.60 USD , PureTech Health PLC is Undervalued By Fair .
What is PureTech Health PLC (PRTC) fair value?
PRTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of PureTech Health PLC (PRTC) is between +Inf to +Inf according to relative valuation methord.
How does PRTC's valuation metrics compare to the industry average?
The average P/S ratio for PRTC's competitors is 4861.95, providing a benchmark for relative valuation. PureTech Health PLC Corp (PRTC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for PureTech Health PLC (PRTC) as of Jan 11 2026?
As of Jan 11 2026, PureTech Health PLC (PRTC) has a P/B ratio of 10.96. This indicates that the market values PRTC at 10.96 times its book value.
What is the current FCF Yield for PureTech Health PLC (PRTC) as of Jan 11 2026?
As of Jan 11 2026, PureTech Health PLC (PRTC) has a FCF Yield of -24.75%. This means that for every dollar of PureTech Health PLC’s market capitalization, the company generates -24.75 cents in free cash flow.
What is the current Forward P/E ratio for PureTech Health PLC (PRTC) as of Jan 11 2026?
As of Jan 11 2026, PureTech Health PLC (PRTC) has a Forward P/E ratio of -5.62. This means the market is willing to pay $-5.62 for every dollar of PureTech Health PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for PureTech Health PLC (PRTC) as of Jan 11 2026?
As of Jan 11 2026, PureTech Health PLC (PRTC) has a Forward P/S ratio of 0.00. This means the market is valuing PRTC at $0.00 for every dollar of expected revenue over the next 12 months.